HistoGenetics Wins Multi-Year Contract for HLA Typing Using PacBio Sequencing
Monday, August 1, 2016
HLA typing, the analysis of genes in the human leukocyte antigen region of the human genome, is of critical importance for research in tissue transplantation matching, autoimmune disease-association studies, drug hypersensitivity research, and other applications. These genes are highly polymorphic and contain thousands of alleles that code for proteins important in recognizing foreign antigens. This complexity has made analyzing them with other sequencing technologies both challenging and costly. In contrast, the long reads provided by Single Molecule, Real-Time (SMRT®) Sequencing are ideally suited for accurate allele-level genotyping of the HLA region.
“In HLA typing, there is no room for errors. The combination of PacBio’s high accuracy and long read lengths to accurately sequence and phase HLA genes is the new gold standard in the field,” said Dr.
“HistoGenetics was early to recognize the value in having full sequences for HLA typing, and we’ve worked closely with them over the last two years as they’ve developed high-throughput workflows on their expanding base of PacBio RS II Systems,” said Dr.
About Pacific Biosciences
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, expected benefits from the contract received by HistoGenetics, future demand, capacity increases or investments by HistoGenetics with regard to SMRT Sequencing products or technology and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Nicole Litchfield415.793.6468 firstname.lastname@example.org Investors: Trevin Rard650.521.8450 email@example.com
News Provided by Acquire Media